Adeno-Associated Virus (AAV)
Concept Map
Exploring the Adeno-Associated Virus (AAV) as a vector in gene therapy, this overview highlights its non-pathogenic nature, small size, and single-stranded DNA genome. AAV's ability to infect various tissues without causing disease and its use in treating genetic disorders like hemophilia and inherited retinal diseases are discussed. The text compares AAV to Adenovirus, outlines AAV's life cycle, production methods, and gene therapy applications, and touches on its interactions with bacterial chromosomes.
Summary
Outline
Overview of Adeno-Associated Virus (AAV) in Gene Therapy
Adeno-Associated Virus (AAV) is a non-pathogenic virus from the Parvoviridae family and Dependoparvovirus genus, characterized by its small size and single-stranded DNA genome of approximately 4.7 kilobases. The virus is encapsulated in a protein shell, or capsid, which facilitates its entry into host cells. AAV's ability to infect a wide range of tissues without causing disease makes it an ideal vector for gene therapy. It is used to deliver therapeutic genes to cells to treat genetic disorders, including hemophilia and inherited retinal diseases. AAV vectors are designed to establish long-term gene expression, which is beneficial for sustained therapeutic effects.Comparative Analysis of AAV and Adenovirus
Adeno-Associated Virus (AAV) and Adenovirus are both members of the virus kingdom Varidnaviria and share characteristics such as a non-enveloped structure and DNA genomes. However, they differ in several aspects. AAV is smaller, approximately 20-25 nm in diameter, with a single-stranded DNA genome, and typically integrates into the host genome, leading to persistent, non-lytic infections. In contrast, Adenovirus is larger, around 70-90 nm, with a double-stranded DNA genome, and often causes acute, lytic infections that can kill the host cell. While AAV is favored for gene therapy due to its safety and long-term expression, Adenovirus is used in vaccine development and gene expression studies due to its high transduction efficiency and transient expression.The Life Cycle and Biological Structure of AAV
The AAV life cycle commences with the virus binding to a host cell and transferring its genome into the nucleus. Inside the nucleus, the single-stranded DNA is converted into a double-stranded form, which is then replicated and transcribed into mRNA. This mRNA is translated into viral proteins that assemble into new virions. The AAV capsid is primarily composed of three proteins: VP1, VP2, and VP3, with VP3 being the most prevalent. The capsid's function is to safeguard the viral genome, which contains the genes necessary for replication and capsid formation, as well as Inverted Terminal Repeats (ITRs) that are crucial for replication and packaging of the viral genome.Production and Purification of AAV for Research and Therapy
The production of AAV for research and therapeutic purposes typically involves the transfection of HEK293 cells with three separate plasmids: one containing the AAV replication (Rep) and capsid (Cap) genes, a second helper plasmid with essential adenoviral genes, and a third with the therapeutic gene flanked by AAV ITRs. After viral replication and assembly within the cells, the AAV is harvested and purified using methods such as ultracentrifugation, ion-exchange chromatography, and affinity chromatography to ensure high purity and potency. The production process is carefully controlled to optimize yield and quality, which are critical for the success of gene therapy applications.The Role of AAV in Gene Therapy Applications
AAV vectors used in gene therapy are engineered to carry a therapeutic gene within the ITRs, excluding any viral genes that could lead to disease. These vectors are introduced into patients, often through injection, to target specific cells and deliver the therapeutic gene to the nucleus. AAV's capability to transduce both dividing and non-dividing cells and to maintain long-term expression of the therapeutic gene makes it a versatile tool for treating a variety of genetic diseases. Despite its advantages, challenges such as limited packaging capacity, potential immune responses, and the complexity of vector production must be addressed to optimize the therapeutic potential of AAV vectors.Interactions Between AAV and Bacterial Chromosomes
AAV's interaction with bacterial chromosomes is a subject of research interest, particularly in the context of lysogenic cycles where the virus integrates into the host genome and replicates alongside it. This integration can confer certain advantages to the bacterium, such as protection against superinfection by similar viruses. While AAV is known to integrate into human chromosomes at a specific site, its behavior in bacterial systems is less well-characterized. Understanding AAV's interactions with bacterial chromosomes could provide insights into viral persistence, gene therapy vector design, and bacterial resistance mechanisms.
Show More
Characteristics of AAV
Size and Genome
AAV is a small virus with a single-stranded DNA genome of approximately 4.7 kilobases
Capsid Structure and Function
Composition of Capsid
The AAV capsid is primarily composed of three proteins: VP1, VP2, and VP3
Role of Capsid
The capsid protects the viral genome and contains essential genes and Inverted Terminal Repeats (ITRs) for replication and packaging
Life Cycle
AAV enters host cells, converts its DNA into a double-stranded form, replicates and transcribes its genes, and assembles new virions
Applications of AAV
Gene Therapy
AAV is used as a vector to deliver therapeutic genes to treat genetic disorders, with the ability to establish long-term gene expression
Vaccine Development and Gene Expression Studies
Adenovirus is used for vaccine development and gene expression studies due to its high transduction efficiency and transient expression, while AAV is favored for gene therapy due to its safety and long-term expression
Production and Purification of AAV
Production Process
AAV is produced by transfecting HEK293 cells with three plasmids containing essential genes and the therapeutic gene flanked by AAV ITRs
Purification Methods
Ultracentrifugation
AAV is purified using ultracentrifugation to ensure high purity and potency
Chromatography
Ion-exchange and affinity chromatography are used to purify AAV
Challenges and Future Directions
Limitations of AAV Vectors
Challenges such as limited packaging capacity, potential immune responses, and complex production processes must be addressed to optimize the therapeutic potential of AAV vectors
AAV Interactions with Bacterial Chromosomes
Research on AAV's interactions with bacterial chromosomes could provide insights into viral persistence, gene therapy vector design, and bacterial resistance mechanisms
Adeno-Associated Virus (AAV)
Learn with Algor Education flashcards
Click on each Card to learn more about the topic
00
AAV Family and Genus
Adeno-Associated Virus belongs to Parvoviridae family and Dependoparvovirus genus.
01
AAV Genome Characteristics
AAV has a single-stranded DNA genome, approximately 4.7 kilobases in size.
02
AAV Capsid Function
The capsid of AAV facilitates entry into host cells by encapsulating the viral DNA.
